ritonavir and Carcinoma--Lewis-Lung

ritonavir has been researched along with Carcinoma--Lewis-Lung* in 1 studies

Other Studies

1 other study(ies) available for ritonavir and Carcinoma--Lewis-Lung

ArticleYear
Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.
    Clinical pharmacokinetics, 2015, Volume: 54, Issue:5

    Understanding transmembrane transport provides a more complete understanding of the pharmacokinetics of a drug and mechanistic explanations for drug-drug interactions. Here, the transmembrane transport of danoprevir (hepatitis C virus protease inhibitor) and the effects of ritonavir and ciclosporin on transmembrane transport of danoprevir were evaluated and clinical pharmacokinetic studies of danoprevir co-administered with/without ritonavir and ciclosporin were conducted.. Transcellular transport of danoprevir was evaluated in Lewis lung cancer porcine kidney, Madin-Darby canine kidney, or Chinese hamster ovary cells transfected with human transport proteins, and in human hepatocytes. The pharmacokinetics of intravenous and oral danoprevir administered with/without ritonavir, and the impact of ciclosporin on danoprevir pharmacokinetics were evaluated in randomized, open-label, crossover studies in healthy subjects.. Danoprevir transport in vitro involved organic anion transporting polypeptide (OATP) 1B1, OATP1B3, P-glycoprotein, and multidrug resistance protein-2, but not breast cancer resistance protein. Ritonavir and ciclosporin inhibited transport of danoprevir by human hepatocytes. The pharmacokinetics of intravenous danoprevir 6 mg were not altered by oral ritonavir 100 mg. In contrast, exposure to oral danoprevir 100 mg increased two- to threefold when co-administered with ritonavir. Absolute bioavailability of danoprevir 100 mg was low (1.15%), but increased more than threefold (3.86%) when co-administered with ritonavir. Oral ciclosporin 100 mg increased exposure to intravenous danoprevir 2 mg and oral ritonavir 100 mg.. Collectively, these studies provide insight into the transmembrane transport and pharmacokinetics of danoprevir and the mechanisms that underlie a recently reported, three-way drug-drug interaction involving danoprevir, ritonavir, and ciclosporin.

    Topics: Adolescent; Adult; Animals; Antiviral Agents; Biological Availability; Carcinoma, Lewis Lung; CHO Cells; Cricetinae; Cricetulus; Cross-Over Studies; Cyclopropanes; Cyclosporine; Dogs; Drug Interactions; Female; Hepatocytes; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Madin Darby Canine Kidney Cells; Male; Membrane Transport Proteins; Middle Aged; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Swine; Young Adult

2015